34161-24-5 Usage
Description
1-(2-[4-Chlorophenoxy]acetyl)-4-(3,4-methylenedioxybenzyl)piperazine is a complex organic compound with a molecular structure that features a piperazine core, a chlorophenoxy acetyl group, and a methylenedioxybenzyl moiety. 1-(2-[4-Chlorophenoxy]acetyl)-4-(3,4-methylenedioxybenzyl)piperazine is characterized by its potential pharmacological properties and may be explored for various therapeutic applications.
Uses
1. Used in Pharmaceutical Applications:
1-(2-[4-Chlorophenoxy]acetyl)-4-(3,4-methylenedioxybenzyl)piperazine is used as a potential drug candidate for the treatment of various medical conditions. Its specific application reason is due to its unique chemical structure, which may interact with biological targets in the human body, modulating physiological processes and providing therapeutic benefits.
2. Used in Research and Development:
In the field of medicinal chemistry, 1-(2-[4-Chlorophenoxy]acetyl)-4-(3,4-methylenedioxybenzyl)piperazine serves as a valuable compound for research and development. It is used as a chemical probe to study the mechanisms of action of various biological pathways and to identify potential drug targets for the development of novel therapeutics.
3. Used in Drug Discovery:
As a part of the drug discovery process, 1-(2-[4-Chlorophenoxy]acetyl)-4-(3,4-methylenedioxybenzyl)piperazine is used to screen for potential pharmacological activities. Its unique structure may provide insights into the design of new drugs with improved efficacy and safety profiles.
4. Used in the Treatment of Melphalan-Induced Vascular Toxicity:
Fipexide, a compound related to 1-(2-[4-Chlorophenoxy]acetyl)-4-(3,4-methylenedioxybenzyl)piperazine, is one of five potential drug candidates to overcome melphalan-induced vascular toxicity. This application highlights the potential therapeutic utility of this class of compounds in mitigating the side effects of certain cancer treatments.
Brand Names:
Attenil 30 conf. 20 mg
Fipexitum
Fipexium
Vigilor 200 mg cpr msfp
Originator
Attentil,Ravizza
Manufacturing Process
25.8 g (0.3 moles) of anhydrous piperazine and 32.5 ml (1.8 moles) of
distilled water (or simply 58.3 g (0.3 moles) of piperazine hexahydrate) are
loaded into a 250 ml flask provided with an agitator, a thermometer and a
reflux condenser, together with 51.2 g (0.3 moles) of piperonyl chloride,
whereupon 2 g of cetyltrimethylammonium bromide are added to the mixture
with vigorous agitation, and the flask is cooled with water so that the
temperature of the reaction mass under agitation does not rise above 110°C.
Once the exothermic stage is exhausted, the temperature is maintained at
130°C by an external oil bath, for 90 min under agitation.After cooling, a solid mass is obtained which is taken up with 400 ml of an
aqueous solution containing 10% by weight of caustic soda to dissolve the
product from the mass. The alkaline solution thus obtained is extracted twice
with 500 ml of chloroform. The extract is washed with water and then
evaporated to dryness. The residue is crystallised from 96% ethanol.50.5 g (theoretical value 53.18 g) of 1,4-bispiperonylpiperazine as a paleyellowish
white crystals are obtained with a melting point of 155-156°C; the
hydrochloride melts with decomposition above 260°C.Preparation of fipexidum hydrochloride:106.3 g (0.3 moles) of 1,4-bispiperonylpiperazine are dissolved in 750 ml of
hot benzene in a 2,000 ml flask provided with a stirrer and a reflux condenser
and 38 g (0.45 moles) of dry, powdered sodium bicarbonate are added. After
cooling to ambient temperature, 92.3 g (0.45 moles, corresponding to 63 ml)
of the chloride of p-chlorophenoxyacetic acid are added slowly, with agitation,
and the mixture is heated under reflux for 7 hours. The benzene is then
almost totally recovered by distillation at atmospheric pressure and the
residue is evaporated to dryness under vacuum. The solid residue thus
obtained is taken up with 400 ml of aqueous solution at 10% sodium
hydroxide (1 mole) and the alkaline liquid phase is extracted twice with 600
ml of chloroform. The chloroform extracts are joined together and washed
with a little water and then agitated vigorously with a solution of 200 ml of
concentrated hydrochloric acid in 300 ml of water. An abundant white
precipitate is obtained. After filtration under vacuum, the precipitate is treated
with boiling ethanol; the 1-((p-chlorophenoxy)acetyl)-4-piperonylpiperazine
hydrochloride (fipexide hydrochloride) passes into solution while the
dihydrochloride of hydrochloric acid remains undissolved and is separated by
filtration while hot. The alcoholic filtrate is cooled, with consequent slow
crystallization of the fipexide hydrochloride. 70.2 g of the product are obtainedwith a yield of 55%; melting point is (in Kofler) 228-230°C.
Therapeutic Function
Antidepressant, Psychostimulant
World Health Organization (WHO)
Fipexide, a stimulant of the central nervous system, was
introduced in 1973 for the treatment of depression and memory defects. Following
its association with hepatic and hemopoietic disorders, particularly in children, the
drug was withdrawn in France. Although not widely marketed, it may still remain
registered elsewhere.
Check Digit Verification of cas no
The CAS Registry Mumber 34161-24-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,4,1,6 and 1 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 34161-24:
(7*3)+(6*4)+(5*1)+(4*6)+(3*1)+(2*2)+(1*4)=85
85 % 10 = 5
So 34161-24-5 is a valid CAS Registry Number.
InChI:InChI=1/C20H21ClN2O4/c21-16-2-4-17(5-3-16)25-13-20(24)23-9-7-22(8-10-23)12-15-1-6-18-19(11-15)27-14-26-18/h1-6,11H,7-10,12-14H2